Breakthrough health products remain a good investor focus

Framlington continues to believe novel and breakthrough products are an important investment focus in the healthcare area. There is still a full and very interesting pipeline of much-needed improved therapies. Not only are many companies actively looking to acquire or collaborate around such products, but they are more likely to avoid reimbursement pressures and regulatory delay. There has been inconsistent leadership at the US Food and Drug Administration (FDA) at a time when the FDA is going through a challenging period. The high profile withdrawal of the COX2 inhibitors, such as Merck'...